With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

DelveInsight's "TIBSOVO Market Size, Forecast, and Market Insight Report" highlights the details around TIBSOVO, the first ...

The therapy is undergoing Phase I clinical development. Credit: Alex_Traksel/Shutterstock. Servier and Black Diamond Therapeutics have signed a licensing agreement ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset ...

Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class ...

Black Di­a­mond Ther­a­peu­tics has found a buy­er for an ear­ly-stage tar­get­ed can­cer drug, which was brushed to the side last year as it fo­cused re­sources … ...

Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond ...

SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...

Black Diamond has got itself a longer runway, securing a licensing deal with French pharmaceutical group Servier for an early-stage small molecule cancer drug Black Diamond backburnered last year. The ...

French independent pharma firm Servier and USA-based Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...